Understand the source comparison
Can Peptides Help DNA Damage Repair: Research vs Clinical Translation Comparison
Thymic peptides (thymalin, thymosin α1) PARP-1 upregulation, immune modulation, Nrf2 pathway activation Multiple RCTs showing 25–35% reduction in DNA damage biomarkers (comet assay, 8-OHdG) over 8–12 weeks Aging research, radiation protection protocols, post-c
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymic peptides (thymalin, thymosin α1)
- PARP-1 upregulation, immune modulation, Nrf2 pathway activation
- Multiple RCTs showing 25–35% reduction in DNA damage biomarkers (comet assay, 8-OHdG) over 8–12 weeks
- Aging research, radiation protection protocols, post-chemotherapy recovery studies
- Strongest mechanistic and clinical evidence. Used in Eastern European clinical settings for decades with established safety profile
- Neuroprotective peptides (cerebrolysin, Dihexa)
- BDNF receptor activation, PI3K/Akt signalling, transcriptional upregulation of BRCA1/p53
- Preclinical models show 40–50% reduction in neuronal DNA fragmentation under oxidative stress
- Neurodegenerative disease research, traumatic brain injury models, cognitive aging studies
- Promising preclinical data. Mechanism is well-characterised but fewer human biomarker studies than thymic peptides
- Mitochondrial-targeted (SS-31, MOTS-c)
- Mitochondrial membrane stabilisation, reduction of ROS leakage, enhanced ATP production for repair processes
- Consistent 35–50% reduction in mitochondrial and nuclear DNA oxidation markers in animal models
- Metabolic disease research, cardiac aging studies, exercise performance optimisation
- Indirect but meaningful effect. Addresses root cause (mitochondrial dysfunction) rather than just symptoms
- Growth hormone secretagogues (MK 677, CJC-1295)
- IGF-1 elevation, mitochondrial biogenesis, increased cellular energy availability
- Observational correlation between IGF-1 levels and reduced mtDNA deletions (34% improvement in one 2023 study)
- Sarcopenia research, age-related mitochondrial decline, metabolic health optimisation
- Secondary DNA repair benefits through improved cellular energy status. Not a direct repair pathway activator